Amniofix in treatment of osteoarthritis of knee | 6626
Rheumatology: Current Research

Rheumatology: Current Research
Open Access

ISSN: 2161-1149 (Printed)

Amniofix in treatment of osteoarthritis of knee

5th International Conference of Orthopedic Surgeons and Rheumatology

June 16-17, 2016 Alicante, Spain

Ashish Anand


Posters & Accepted Abstracts: Rheumatology (Sunnyvale)

Abstract :

Amniotic membrane has been used extensively in management of non-healing ulcers and has been reported to be successful in 85% of the cases. In recent years, there have been several studies using rat models which support the use of amniotic membranes and chorion in the regeneration and repair of soft tissues. These finding have lead to interest in their use in OA. The potential for cHorion and amnion to moderate osteoarthritis, as of yet, has not been explored in length; however indirect evidence suggest they may have advantageous effects on cartilage. The use of amniotic membrane (AM) in the form of HAMCs and dHACM is an appealing therapeutic option for the repair of articular cartilage damage caused by OA. We report our case series of 10 patients of variable age group who had failed all conservative treatment options and were unwilling for surgery. Patients were injected with Amniofix injection and were followed at 4 weeks and 8 weeks and 6 months. Patients reported improvement in there VAS pain levels of more than 65 percent as well an improvement in there functional capacity measured with regards to walking distance. No Failures were reported at short term follow up of 6 months and there were no side effects. Out short case series suggests that Amniofix can be used in treatment of arthritic pain and thereby delaying the need for Knee Arthroplasty. To the best of our knowledge there is no other study described in English Literature elucidating the benefits of Amniofix in osteoarthritis and ours is the first one.

Biography :